Gilliland Dwight Gary
Known title: DirectorCIK: 0001603769
Associated companies
Transaction History
| LH | ▼ Sell | Open Market | 2,000 | $530K | 7/30/2025 | View on chart |
| LH | ▲ Buy | Option Exercise | 944 | — | 2/6/2025 | View on chart |
| LH | ▼ Sell | Open Market | 1,000 | $241K | 12/2/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 947 | — | 2/7/2024 | View on chart |
| LH | ▲ Buy | Option Exercise | 742 | — | 2/11/2023 | View on chart |
| LH | ▲ Buy | Option Exercise | 771 | — | 2/2/2022 | View on chart |
| LH | ▼ Sell | Open Market | 357 | $108K | 12/15/2021 | View on chart |
| LH | ▼ Sell | Open Market | 18 | $5K | 12/15/2021 | View on chart |
| LH | ▼ Sell | Open Market | 25 | $8K | 12/15/2021 | View on chart |
| LH | ▼ Sell | Open Market | 100 | $30K | 12/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Labcorp to Acquire OPKO Health's BioReference Assets for $722M
Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.
Labcorp to Acquire OPKO Health's BioReference Assets for $722M. Labcorp has agreed to acquire select assets from OPKO Health's BioReference division for $722 million. This move expands Labcorp's capabilities in the diagnostics sector, a key area for the company's growth. The stock is currently trading near its 52-week high, reflecting investor interest in this strategic acquisition.